{"title":"gammaCore Device for Chronic Posttraumatic Headache Pain Management in Veterans With Comorbid Mood Disorders: A Case Report.","authors":"Jason Parmar, Darlene Makulski","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic posttraumatic headache (CPTHA) is a prevalent condition following traumatic brain injury, especially among veterans, with a significant impact on quality of life. Traditional treatments often lack efficacy and evidence-based support.</p><p><strong>Case report: </strong>We report the case of a 46-year-old male veteran with CPTHA, nonresponsive to standard therapies, including botulinum toxin A and oral medications. The patient underwent treatment with the gammaCore vagus nerve stimulator, a US Food and Drug Administration-cleared device intended for migraine and cluster headache management.</p><p><strong>Conclusions: </strong>Following initiation of gammaCore therapy, the patient experienced a marked reduction in headache intensity and frequency, alongside significant improvements in anxiety levels. These outcomes suggest that gammaCore may be a promising noninvasive treatment option for CPTHA, particularly in patients with coexisting mood disorders. Further research is warranted to validate these findings and establish gammaCore's role in CPTHA management.</p>","PeriodicalId":520525,"journal":{"name":"Pain medicine case reports","volume":"9 2","pages":"119-122"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain medicine case reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Chronic posttraumatic headache (CPTHA) is a prevalent condition following traumatic brain injury, especially among veterans, with a significant impact on quality of life. Traditional treatments often lack efficacy and evidence-based support.
Case report: We report the case of a 46-year-old male veteran with CPTHA, nonresponsive to standard therapies, including botulinum toxin A and oral medications. The patient underwent treatment with the gammaCore vagus nerve stimulator, a US Food and Drug Administration-cleared device intended for migraine and cluster headache management.
Conclusions: Following initiation of gammaCore therapy, the patient experienced a marked reduction in headache intensity and frequency, alongside significant improvements in anxiety levels. These outcomes suggest that gammaCore may be a promising noninvasive treatment option for CPTHA, particularly in patients with coexisting mood disorders. Further research is warranted to validate these findings and establish gammaCore's role in CPTHA management.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
